Isolation of anti-desmoglein 1 antibodies by phage display of pemphigus foliaceus autoantibodies
This invention relates to compositions and methods for the use of anti-autoimmune reagents that specifically bind to anti-desmoglein antibodies, which are responsible for pemphigus foliaceus. In addition, the invention relates to methods and compositions for inhibiting the expression or function of a variable region of an anti-desmoglein (anti-Dsg) pathogenic autoantibody.
1. An isolated anti-desmoglein 1 (Dsg1) antibody or fragment thereof comprising a heavy chain (V H ) encoded by the gene selected from the group consisting of VH1-18, VH1-08, VH3-09, VH3-07, VH3-30, VH4-b, VH3-53, VH3-66, and any combination thereof; and a light chain (V L ) encoded by the gene selected from the group consisting of A30, B3, L1, L2, L8, L11, L12, LFVK431, O12O2, O18O8, 1c, 1e, 1g, 6a, 3h, and any combination thereof.
2. The antibody or fragment thereof of claim 1 , wherein the antibody is pathogenic and comprises a consensus sequence represented by Asp-X-X-X-Trp (SEQ ID NO: 259) or Glu-X-X-X-Trp (SEQ ID NO: 260).
3. The antibody or fragment thereof of claim 1 , comprising a heavy chain variable domain comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 216-258, and any combination thereof.
4. The antibody or fragment thereof of claim 1 , comprising a light chain variable domain comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 173-215, and any combination thereof.
5. The antibody or fragment thereof of claim 1 , comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 44-86, and any combination thereof.
6. The antibody or fragment thereof of claim 1 , wherein said antibody or fragment thereof is a single chain Fv (scFv), a Fab, a (Fab′) 2 or a (scFv′) 2 .
7. A composition comprising an anti-autoimmune antibody, wherein said anti-autoimmune antibody specifically binds to an anti-desmoglein 1 (Dsg1) antibody or fragment thereof comprising a heavy chain (V H ) encoded by the gene selected from the group consisting of VH1-18, VH1-08, VH3-09, VH3-07, VH3-30, VH4-b, VH3-53, VH3-66, and any combination thereof; and a light chain (V L ) encoded by the gene selected from the group consisting of A30, B3, L1, L2, L8, L11, L12, LFVK431, O12O2, O18O8, 1c, 1e, 1 g, 6a, 3h, and any combination thereof.
8. The composition of claim 7 , wherein said anti-autoimmune antibody is selected from the group consisting of, a humanized antibody, a recombinant antibody, and any combination thereof.
9. The composition of claim 7 , wherein said antibody or fragment thereof of comprises a heavy chain variable domain comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 216-258, and any combination thereof.
10. The composition of claim 7 , wherein said antibody or fragment thereof of comprises a light chain variable domain comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 173-215, and any combination thereof.
11. The composition of claim 7 , wherein said antibody or fragment thereof of comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 44-86, and any combination thereof.
12. A method of inhibiting the binding of an anti-desmoglein 1autoantibody or fragment thereof to desmoglein, said method comprising contacting the anti-desmoglein 1 autoantibody or fragment thereof with a composition comprising an anti-autoimmune reagent that specifically binds to an anti-desmoglein 1 autoantibody or fragment thereof comprising a heavy chain (V H ) encoded by the gene selected from the group consisting of VH1-18, VH1-08, VH3-09, VH3-07, VH3-30, VH4-b, VH3-53, VH3-66, and an combination thereof; and a light chain (V L ) encoded by the gene selected from the group consisting of A30, B3, L1, L2, L8, L11, L12, LFVK431, O12O2, O18O8, 1c, 1e, 1g, 6a, 3h, and any combination thereof.
13. The method of claim 12 , wherein said anti-desmoglein 1 antibody or fragment thereof comprises a heavy chain (V H ) encoded by the gene selected from the group consisting of VH1-18, VH1-08, VH3-09, VH3-07, VH3-30, VH4-b, VH3-53, VH3-66, and any combination thereof.
14. The method of claim 12 , wherein the antibody or fragment thereof of comprises a heavy chain variable domain comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 216-258, and any combination thereof.
15. The method of claim 12 , wherein the antibody or fragment thereof of comprises a light chain variable domain comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 173-215, and any combination thereof.
16. The method of claim 12 , wherein the antibody or fragment thereof of comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 44-86, and any combination thereof.
17. The method of claim 12 , wherein the antibody or fragment thereof is associated with the pathology of pemphigus foliaceus (PF).